Report Highlights
The global chiral technology market was worth nearly $5.3 billion in 2011. This market is expected to increase at a CAGR of 6.5% from 2011 to 2016 and will approach $7.2 billion by the end of the forecast period.
Report Scope
The scope of this study encompasses the chiral markets with their usage in the pharmaceutical, biotechnical and agrochemical markets. BCC analyzes each market and its applications by its need for chiral products, their regulatory environment, technology involved, market projections and market share. Technological issues include the latest trends and developments.
Analyst Credentials
Shalini Shahani Dewan focuses on pharmaceuticals and biotechnology and has been a BCC Research contributor since 2002 as both an analyst and project manager. She has explored a wide range of topics and companies, including working for Johnson & Johnson doing market surveillance. She has an undergraduate degree in pharmacy and master's degree in medicinal chemistry. She resides in the Bay Area.
Report Highlights
-
Global sales of chiral technology products in 2008 were $4.3 billion and with 3.3% growth, the sales reached $4.5 billion in 2009. This market is expected to rise at a compound annual growth rate (CAGR) of 2.8% and reach $5.1 billion by 2014.
-
The chiral technology market is led by chiral synthesis products with more than 80% share. This sector was worth $3.6 billion in 2009 and is projected to increase at a 2.2% compound annual growth rate (CAGR) to $4 billion in 2014.
-
The chiral analysis market was valued at $714 million in 2009. This segment is estimated to grow at a compound annual growth rate (CAGR) of 5.5% to reach $936 million in 2014.
Report Highlights
-
The total U.S. market for chiral technology reached $1.2 billion in 2003. Rising at an average annual growth rate (AAGR) of 8.8%, this market is expected to exceed $1.8 billion in 2008.
-
Chiral manufacturing dominates, with revenues of more than $1 billion in 2003 and rising to $1.6 billion at an AAGR of 9.2% in 2008.
-
The chiral analysis market was $164.6 million by 2003 and should rise to $226.4 million by 2008, for an AAGR of 6.6%.
-
The worldwide market for chiral-enabling products was expected to reach $2,998 million by the end of 2003 and rise at an AAGR of 9.1% through 2008.
Report Highlights
-
Manufactured enantiomeric products, produced either by racemate separation (resolution, the dominant technology to date) or by specific chiral synthesis to produce single isomer products. Although chiral resolution still is the dominant commercial technology, the value of its enabling products is much less. It only was about $103 million in 1999, compared to more than $1.6 billion that year for chiral synthesis-enabling products. The reason lies in the recovery and reuse of most separation products and the high cost (and use) of chiral chemical intermediates; the latter are the single, largest type of chiral enabling product at about $1.6 billion in 1999. We forecast continued healthy growth for all chiral manufacturing products, from a total of $1.75 billion in 1999 to almost $2.8 billion in 2004, at an average annual growth rate (AAGR) of almost 10%.
-
Chiral analysis products are materials that enable scientists to analyze chiral products and mixtures. This market, valued at about $160 million in 1999 and growing at 5.5% overall to $209 million in 2004. It is dominated by analytical chromatography, especially liquid chromatography (mainly HPLC). This latter technology accounted for $121 million of the 1999 market.
Related Reports
Metamaterials: Technologies and Global Markets
BCC estimates the global market for metamaterials was worth $222.3 million in 2010 and $256.1 million in 2011. BCC expects the market to grow to $758.7 million by 2016, a compound annual growth rate (CAGR) of 24.3% since 2011, and to reach nearly $1.9 billion by 2021, a CAGR of 19.6% between 2016 and 2021.
Liver Disease Treatments: The Global Market
In 2009, the global market for drugs used to treat liver disease was worth approximately $12.4 billion. Sales in 2010 decreased and the market did not see much progress, causing overall global sales to remain stagnant at $12.4 billion. Estimated sales in 2011 a projected $12 billion (excluding protease inhibitors). The market is expected to rise at a CAGR of 3.3% and reach nearly $14.2 billion by 2016.
Advanced Drug Delivery Systems: Technologies and Global Markets
The global market for drug delivery systems in 2010 was $131.6 billion and is expected to increase to $137.8 billion by the end of 2011. The market is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016.
Antiseptics and Disinfectants
The global market for antiseptics and disinfectants in 2009 was at about $3.4 billion, and with a 12% increase, sales reached about $3.8 billion in 2010. The market is expected to rise at a compound annual growth rate (CAGR) of 11.1% and reach $7.1 billion by 2016.
Recent Reports
Bioprocess Optimization and Digital Bio-manufacturing: Global Markets
The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 and is projected to reach $39.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2024 to 2029.
Global DNA Sequencing: Research, Applied and Clinical Markets
The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.
Artificial Intelligence (AI) in Cancer
The global market for artificial intelligence (AI) in cancer is estimated to increase from $2.2 billion in 2024 to reach $6.3 billion by 2029, at a compound annual growth rate (CAGR) of 23.1% from 2024 through 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Top Trending Reports
Single-use Technologies for Biopharmaceuticals: Global Markets
The global market for single-use technologies for biopharmaceuticals is expected to grow from $6.5 billion in 2024 and is projected to reach $11.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 11.6% during the forecast period of 2024 to 2029.
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for Cell and Gene Therapy (CGT) Tools and Reagents is estimated to increase from $10.0 billion in 2024 to reach $16.7 billion by 2029, at a compound annual growth rate (CAGR) of 10.8% from 2024 through 2029.
Medical Devices Industry: Competitive Landscape
The global market for medical devices is estimated to increase from 810.4 billion in 2024 to reach $1.3 trillion by 2029, at a compound annual growth rate (CAGR) of 9.8% from 2024 through 2029.
Global Market Opportunities and Competitive Landscape for CDMO
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
Chronic Disease Management: Therapeutics, Device Technologies and Global Markets
The global market for chronic disease management therapeutics and device technologies was valued at $675.0 billion in 2023. It is projected to grow from $726.3 billion in 2024 to $1.1 trillion by 2029, at a compound annual growth rate (CAGR) of 8.1% from 2024 through 2029.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More